NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
Oncology treatment pioneer NovoCure (NASDAQ:NVCR) reported mixed fourth-quarter 2024 earnings on Thursday, Feb. 27. Q4 revenue matched analysts' consensus expectations at $161.3 million and jumped 21% year over year. However, NovoCure's GAAP EPS loss of $0.61 was worse than the estimated $0.34 loss.
Despite these mixed results, NovoCure achieved significant strides with FDA approvals and positive clinical trial outcomes, indicating promising avenues for growth.
Source: NovoCure. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. EBITDA = Earnings before interest, taxes, depreciation, and amortization.
